From: Commercial and public payer opioid analgesic prescribing policies: a case study
Specific Action | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | Total | # payers implemented |
---|---|---|---|---|---|---|---|---|---|
LIMITATIONS on number days initial prescrpiton | 8 | 4 | 4 | 7 | 11 | 22 | 27 | 83 | 8 |
PRIOR AUTHORIZATION on initial prescription | 9 | 7 | 5 | 9 | 13 | 16 | 18 | 77 | 8 |
Formulary limitation | 5 | 1 | 3 | 5 | 10 | 12 | 24 | 60 | 8 |
Registry of patients | 11 | 4 | 6 | 6 | 6 | 7 | 18 | 58 | 8 |
Pharmacy safety review/step edit | 4 | 6 | 6 | 9 | 6 | 14 | 12 | 57 | 8 |
PRIOR AUTHORIZATION for long-acting/extended release opioids | 6 | 2 | 5 | 4 | 3 | 6 | 10 | 36 | 8 |
LIMITATIONS on providers | 4 | 6 | 5 | 7 | 3 | 8 | 3 | 36 | 8 |
LIMITATIONS on number refills | 6 | 2 | 3 | 2 | 0 | 10 | 13 | 36 | 7 |
LIMITATIONS on dosages within formulary | 4 | 1 | 2 | 2 | 5 | 7 | 9 | 30 | 7 |
PRIOR AUTHORIZATIONS for refill prescription(s) | 1 | 3 | 2 | 1 | 1 | 8 | 9 | 25 | 7 |
PRIOR AUTHORIZATIONS for higher potency opioids | 2 | 1 | 2 | 1 | 1 | 5 | 9 | 25 | 8 |
Feedback to providers on opioid prescribing | 2 | 2 | 0 | 3 | 0 | 1 | 1 | 9 | 3 |
Incentives to providers | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
Total | 62 | 39 | 43 | 56 | 59 | 116 | 154 | 529 |